| mycophenolate sodium / Generic mfg. |
| Recruiting | 3 | 32 | | | Royal Brisbane, Royal Brisbane Hospital research Foundation, Novartis Pharmaceuticals Australia | Lupus Nephritis patients | | | | |
2008-003540-11: Preventie van ernstige Graft versus Host ziekte na allogene stamcel transplantatie gegeven als immuuntherapie voor patienten met een hematologische ziekte. Een gerandomiseerde fase III studie (HOVON 96 GVHD). |
|
|
| Ongoing | 3 | 500 | Europe | Ciclosporine, Myfortic, cyclophosphamide, Capsule, soft, Tablet, Powder for solution for infusion, Concentrate for solution for infusion, Myfortic 180 mg, Myfortic 360 mg | HOVON Foundation, Dutch Cancer Society, HOVON Foundation, Novartis Pharma BV, Novartis Pharma NV, Fresenius, Dutch Cancer society, Hovon Foundation, Novartis pharma BV, Novartis Pharma Belgium | Graft versus Host Disease, Graft versus Host Disease, Diseases [C] - Cancer [C04] | | | | |
2004-002973-22: Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients |
|
|
| Ongoing | 3 | 250 | Europe | NA, NA, | AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I, AZIENDA POLICLINICO UMBERTO I | Profilaxis of rejection in stable renal transplant patients | | | | |
2010-018353-36: BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation |
|
|
| Ongoing | 3 | 400 | Europe | CERTICAN, CELLCEPT, MYFORTIC, CERTICAN, CELLCEPT, MYFORTIC | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA, GRANDA (A.O. DI RILIEVO NAZIONALE) | Paitents will be enrolled at least one year after heart transplant | | | | |
NCT04877288 / 2018-000237-12: A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications |
|
|
| Recruiting | 3 | 102 | Europe, US | Belatacept, Nulojix, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids | Bristol-Myers Squibb | Renal Allograft Recipients | 05/26 | 01/28 | | |
INSTEAD, NCT05385432: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies |
|
|
| Not yet recruiting | 3 | 244 | NA | Rabbit Anti thymocyte globulin (rATG), Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids, Basiliximab | University Hospital, Tours | Renal Transplant Rejection, Induction Therapy | 03/27 | 03/30 | | |
